| Document |
Document Title |
|
WO/2024/059563A1 |
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.
|
|
WO/2024/051631A1 |
Disclosed are a macrocyclic imidazo[1,2-b]pyridazine compound represented by formula (I) or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer, a tautomer thereof or an isomer mixture thereof, or a...
|
|
WO/2024/054845A1 |
The present disclosure includes, among other things, compounds of formula I as CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
|
|
WO/2024/054851A1 |
The present disclosure includes, among other things, macrocyclic CFTR modulators of formula I, pharmaceutical compositions, and methods of making and using the same.
|
|
WO/2024/054840A1 |
The present disclosure includes, among other things, compounds of formula I (I) as CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
|
|
WO/2024/042146A2 |
The present invention provides covalent fluorescent probes for cannabinoid receptor 2 ("CB2") having the general formula (I) wherein X, n, p, and R1 to R4 are as described herein, compositions including the compounds, processes of manufa...
|
|
WO/2024/008834A1 |
The present invention relates to compounds of formula (I), wherein R1 to R6, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compoun...
|
|
WO/2024/008610A1 |
The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
|
|
WO/2023/215220A1 |
The present disclosure provides, in part, compounds of formula (I), or a stereoisomer and/or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein; pharmaceutical compositions comprising the compounds; a...
|
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
|
WO/2023/205701A1 |
The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, t...
|
|
WO/2023/201320A1 |
The disclosure provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R'-R7 and L are defined herein: Also provided are pharmaceutical compositions, comprising one or more compounds described herein and...
|
|
WO/2023/193440A1 |
Provided is a lurbinectedin crystal form having characteristic absorption peaks at diffraction angles 2θ of 4.55 ± 0.2°, 6.16 ± 0.2°, 7.61 ± 0.2°, 9.17 ± 0.2°, 9.54 ± 0.2°, and 9.89 ± 0.2° in an X-ray powder diffraction patt...
|
|
WO/2023/196429A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibro...
|
|
WO/2023/174138A1 |
Disclosed are an amide compound as represented by formula I, and a preparation method therefor and the use thereof. The disclosed amide compound has selective inhibitory activity on Nav1.8 and can be used as a selective inhibitor for Nav...
|
|
WO/2023/143352A1 |
Disclosed are a nitrogen-containing heterocyclic compound, a preparation method therefor, and a use thereof. Provided is a nitrogen-containing heterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a s...
|
|
WO/2023/103539A1 |
The present invention provides a new method for preparing ET743 and key intermediates thereof. The method adopts photocatalysis to directly convert a compound A into a compound B through a one-step reaction. The method has advantages suc...
|
|
WO/2023/099623A1 |
The present invention encompasses compounds of formula (V) wherein R1a, R1b, R2a, R2b, Z, R4, R5, R14, A, p, X, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical compositi...
|
|
WO/2023/087027A1 |
Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
|
|
WO/2023/078127A1 |
A macrocyclic sulfonamide compound, a preparation method therefor, and a medical use thereof. The macrocyclic sulfonamide compound has a specific structure as represented by formula (I). The macrocyclic sulfonamide compound or a pharmace...
|
|
WO/2023/064501A1 |
Disclosed herein are electrically conductive polymer compositions comprising a polymer and a dispersant, and methods of synthesizing the polymers therein. Also disclosed herein are microelectrode arrays comprising the electrically conduc...
|
|
WO/2023/031958A1 |
The present invention is related to novel process for preparation of Trabectedin which involves less expensive reagents, solvents and the process conditions can be easily adopted for commercial scale.
|
|
WO/2023/015559A1 |
The present disclosure discloses a compound, or a pharmaceutically acceptable salt thereof having the structure of Formula (I), and pharmaceutical compositions including the same, that are inhibitors of one or more RAS proteins and are u...
|
|
WO/2023/011629A1 |
Provided are a pyrrolidone derivative or a stereoisomer thereof, and the use thereof in medicine.
|
|
WO/2023/280970A1 |
The present invention relates to novel inhibitors of α-hemolysin of formula (I) and the use thereof for the prophylaxis and treatment of infections caused by Staphylococcus aureus; especially S. aureus lung infections.
|
|
WO/2023/279041A1 |
Disclosed herein are compounds and methods of treating diseases and/or conditions associated with FGFR inhibition.
|
|
WO/2022/255888A1 |
A compound of formula (I) [MCL-1 ligand moiety] - [linker] - [ligase ligand moiety] (I) or a salt, solvate, hydrate, isomer or prodrug thereof, wherein [MCL-1 ligand moiety] is a compound of Formula (A), Formula (B) or Formula (C) and it...
|
|
WO/2022/253713A1 |
A compound of formula (I); [MCL-1 ligand moiety] - [linker] - [ligase ligand moiety] (I); or a salt, solvate, hydrate, isomer or prodrug thereof, wherein [MCL-1 ligand moiety] is a compound of Formula (A), Formula (B) or Formula (C), and...
|
|
WO/2022/251247A1 |
The present claims are directed to compounds of formulae (I) and (II). Such compounds, pharmaceutically acceptable salts and compositions thereof, are inhibitors of myeloid cell leukaemia 1 (Mcl-1) protein and are useful in the treatment...
|
|
WO/2022/233872A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein n, m, A1, A2, A3, A4, A5, A6, L1, L2, R1, R2, R3, Y and Z are defined herein. Also provided herein are pharmaceutical compositions compris...
|
|
WO/2022/171782A1 |
The present invention relates to compounds of formula (I) wherein XI is as myeloid cell leukemia-1 (MCL-1) inhibitors for the treatment of cancer, such as e.g. prostate, lung, pancreatic, breast, ovarian, and cervical cancer, melanoma, B...
|
|
WO/2022/165148A1 |
The present disclosure provides novel synthetic intermediates useful in the synthesis of MK2 kinase inhibitors.
|
|
WO/2022/145459A1 |
The present invention addresses the problem of providing a compound having Nrf2-activation action. Provided are: compounds represented by general formula (I), or compounds of the lower-polarity group among two groups of diastereomers in ...
|
|
WO/2022/133480A1 |
The present invention provides AHR agonists, composites thereof, and methods of using the same.
|
|
WO/2022/109363A1 |
The present invention discloses compounds of Formula (la), and pharmaceutically acceptable salts, thereof: Formula (Ia) which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprisi...
|
|
WO/2022/076620A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated disea...
|
|
WO/2022/076625A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseas...
|
|
WO/2022/076622A2 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseas...
|
|
WO/2022/076618A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...
|
|
WO/2022/076621A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases, i...
|
|
WO/2022/076626A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...
|
|
WO/2022/076624A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseas...
|
|
WO/2022/064187A1 |
A compound of formula (I-1), or a pharmaceutically acceptable salt or hydrate thereof, formula (I-1) wherein: ring A is a monocyclic 5, 6, or 7-membered heterocycloalkyl ring optionally substituted by one or more substituents selected fr...
|
|
WO/2022/032284A1 |
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...
|
|
WO/2022/008674A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2021/255257A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2021/239862A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2021/231737A1 |
The disclosure is directed to crystalline forms of the compound of Formula I: Formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and p...
|
|
WO/2021/218896A1 |
The present disclosure relates to an ecteinascidin derivative, a preparation method therefor and a medical use thereof, in particular, to a compound represented by general formula (I), a medical use thereof and a preparation method there...
|
|
WO/2021/211922A1 |
The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I) as well as methods of their use and preparation, are also described.
|
